Drug Trial Radar · NCT05206877
Topical Insulin for Glaucoma
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Apr 1, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Conditions
- Glaucoma
Interventions
Insulin, 4 unitsDrug
Topical insulin 100 U/ml, 1 drop per day
Insulin, 20 unitsDrug
Topical insulin 500 U/ml, 1 drop per day
insulin, 4 units twice dailyDrug
1 drop of low dose insulin twice daily.
insulin, 20 units twice dailyDrug
1 drop of high dose insulin twice daily
insulin, 4 units three times dailyDrug
1 drop of low dose insulin three times daily.
insulin, 20 units three times dailyDrug
1 drop of high dose insulin three times daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Related Adverse EventsTime frame: During treatment period, difference from baseline to post-treatment up to 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Byers Eye Institute at Stanford University
Palo Alto, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.